SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tria is a self-custodial neobank and cross-chain payments infrastructure designed to make onchain money usable in everyday life. It combines card spending, trading, and earning in a single account experience, so users can move value across chains without manually bridging assets, switching networks, or managing chain-specific steps. Under the hood, Tria routes every action through BestPath, an ultra-fast routing and execution layer that takes an intent like “spend,” “swap,” “send,” or “earn” and completes it end-to-end on the optimal path. Tria operates in two modes: a consumer app that includes a Visa-powered card, spot swaps, perpetual futures, and Earn vaults, and a developer and institutional layer that integrates with protocols and ecosystems to embed Tria’s execution rails wherever value already moves. The end goal is simple: one continuous flow for money across chains, with self-custody by default and a product experience that feels effortless for normal users worldwide.

TRIA

Community buzz around TRIA CRYPTO is surging, fueled by expectations of a major national online bank partnership and new exchange listings. Discussions highlight its potential as a prominent banking project in the crypto space, with many anticipating further upward momentum.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is surging after delivering robust earnings driven by exceptional cloud infrastructure growth and a record-breaking backlog, directly addressing investor concerns about its AI-driven capital expenditures and prompting bullish sentiment for a market turnaround. The community is actively discussing the company's strong guidance and its pivot to a core AI infrastructure provider, with many celebrating the dispelling of bearish narratives.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is surging after reporting its first-ever quarterly net profit and strong delivery guidance, igniting bullish sentiment around its unique battery swap ecosystem and in-house AI chip development, though some anticipate continued volatility amid strong market competition.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics is trending after announcing a key development for its SOTERIA Phase 2 trial, sparking a significant surge in retail trading volume and price. As a volatile, recently direct-listed clinical-stage biotech, the community is actively discussing its potential for a short squeeze and further notable price movements.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

RILY is trending following its confirmed NASDAQ compliance and strong preliminary Q4 results, with the community actively discussing its deep undervaluation and high short interest amidst significant debt reduction and appreciating assets like BW, leading to expectations of a major short squeeze.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending with mixed reactions to a recent Supreme Court ruling on tariffs, adding to community debate over whether the stock's persistent slide makes it a "value trap" or a "generational buying opportunity" ahead of its crucial upcoming earnings report.

XAU-9999 is an Ethereum-based meme token that satirizes gold-backed digital assets by offering a symbolic, valueless version of “digital gold” with no physical backing or real-world utility. It is created solely for entertainment, community participation, and cultural parody, reflecting internet-native humor and crypto’s obsession with wealth, status, and digital ownership. The token has no financial utility and exists purely as a social and cultural artifact.

XAU9999

XAU is trending as geopolitical tensions continue to fuel significant safe-haven demand, with community discussions centering on gold's resilience against broader economic uncertainty and shifting Federal Reserve rate expectations.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Edesa Biotech Inc

Edesa Biotech is trending as positive Phase 3 data for its ARDS drug, showing significant mortality reduction, drives community speculation about accelerated regulatory pathways or a potential buyout. This surge in interest is amplified by the CEO's consistent open-market share purchases and recent institutional investment.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending due to key market access wins for its fibromyalgia drug, Tonmya, with UnitedHealthcare and Kaiser expanding coverage, alongside the company's uplisting to Nasdaq Global Select, driving bullish community discussion on accelerating sales and short squeeze potential despite historical dilution concerns.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to community frustration and disappointment over its recently announced $350 million convertible senior notes offering, with many questioning the need for new capital given its existing cash reserves and previous buyout rumors. While some speculate the funds might be for strategic acquisitions or new partnerships, others view it as a poor capital decision by management, impacting shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Propel Bio Management LLC Buys 212,457 Shares of Delcath Systems, Inc. $DCTH

Propel Bio Management LLC grew its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 94.0% during the third quarter, according to its most recent filing with the Securities and...

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems, Inc. (Nasdaq: DCTH), (Delcath or the Company) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of...

FY2029 EPS Forecast for Delcath Systems Decreased by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Equities researchers at HC Wainwright dropped their FY2029 EPS estimates for shares of Delcath Systems in a note issued to investors on Monday...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...

Delcath Systems (NASDAQ:DCTH) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Delcath Systems from a "buy" rating to a "hold" rating in a research report on Saturday...

Delcath Systems Q4 Earnings Call Highlights

Delcath Systems (NASDAQ:DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding...

BTIG Research Cuts Delcath Systems (NASDAQ:DCTH) Price Target to $19.00

BTIG Research reduced their target price on shares of Delcath Systems from $23.00 to $19.00 and set a "buy" rating for the company in a report on Thursday...

Delcath Systems Q4 Earnings Assessment

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the Company), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial...

Delcath Systems (DCTH) to Release Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

DCTH
Delcath Systems Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest DCTH News

DCTHDelcath Systems Inc